Buy Talzenna at over 60% savings from US prices.
Non-english packaging - English label and English insert included. Plan in advance - allow us 7 days to ship your medicine
Manufacturer for all European Talzenna:
Excella GmbH & Co. KG
Nürnberger Strasse 12
90537 Feucht
Germany
Information about Talzenna (Talazoparib)
Talzenna (generic name: Talazoparib) is a prescription medication used to treat specific types of cancer. It is classified as a poly(ADP-ribose) polymerase (PARP) inhibitor and works by interfering with the repair of damaged DNA in cancer cells, leading to their death. Talzenna is primarily used to treat breast cancer associated with inherited BRCA mutations and is effective in patients with advanced or metastatic breast cancer who have already undergone other treatments.
Product Highlights
- Talzenna is approved for the treatment of adults with locally advanced or metastatic breast cancer that is HER2-negative and has a BRCA1 or BRCA2 mutation.
- Talzenna is used as a monotherapy for patients who have previously received chemotherapy for breast cancer, particularly in cases of BRCA-mutated cancer.
- Although primarily indicated for breast cancer, Talzenna may also be explored for use in other cancers involving BRCA mutations in clinical trials or off-label settings.
Key Ingredient
Key Benefits
- Talzenna specifically targets cancer cells with BRCA mutations, making it effective for patients with specific genetic mutations.
- Clinical trials have shown that Talzenna can improve progression-free survival in patients with metastatic breast cancer.
- While side effects may occur, Talzenna is generally considered well-tolerated compared to traditional chemotherapy, with fewer systemic side effects like hair loss or nausea.
- Talzenna has shown effectiveness in treating cancers with BRCA mutations, which are often more resistant to conventional treatments.
Direction of Use
- The typical recommended dose of Talzenna is 1 mg once daily, taken orally. It is typically prescribed as one dose per day.
- Talzenna capsules should be swallowed whole, with or without food. The capsules should not be chewed, crushed, or broken.
- If you miss a dose, take it as soon as you remember, unless it's almost time for your next dose. Do not take two doses at once to compensate for a missed dose.
- Treatment with Talzenna is usually continued until disease progression or intolerable side effects develop.
Safety Concerns
- Common side effects may include nausea, fatigue, headaches, anemia, loss of appetite, and low white blood cell counts (leukopenia). Some patients may experience gastrointestinal issues like diarrhea or constipation.
- Serious side effects may include myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), or severe blood disorders. Regular monitoring of blood counts is required during treatment.
- Talzenna should not be used during pregnancy as it may harm the fetus. It is also not advised during breastfeeding, as it may be excreted in breast milk.
- Regular blood tests are required to monitor for potential blood count abnormalities and other serious side effects during treatment.
Avoid Talzenna (Talazoparib) If
- Do not use Talzenna if you are allergic to talazoparib or any of its ingredients.
- Talzenna is contraindicated during pregnancy due to its potential teratogenic effects on the fetus.
- Talzenna should be avoided in patients with severe bone marrow suppression or blood disorders, such as anemia or neutropenia.
- Talzenna should not be used while breastfeeding, as it may pass into breast milk and harm a nursing infant.
